The role of positive selection in hepatitis C virus

Infection, Genetics and Evolution

Volumn 9, Issue 5, 2009, Pages 860-866

  Cuevas, José M ^a,b   Gonzalez, Michael ^a   Torres Puente, Manuela ^a   Jiménez Hernández, Nuria ^a,b,c   Bracho, María A ^a,b,c   García Robles, Inmaculada ^a   González Candelas, Fernando ^a,b,c   Moya, Andrés ^a,b,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c CSISP ^*  (Spain)

Author keywords

Hepatitis C virus; HVR1; HVR2; HVR3; ISDR; PKR BD; Positive selection; V3 domain

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN E2; RIBAVIRIN;

AMINO ACID COMPOSITION; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DOMAIN; TREATMENT DURATION; VIRUS GENOME; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; COMPLEMENTARITY DETERMINING REGIONS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; SELECTION (GENETICS); SEQUENCE ANALYSIS, PROTEIN; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS; MOYA;

EID: 67651087169     PISSN: 15671348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.meegid.2009.05.007     Document Type: Article

References (41)

1. Afdhal N.H. The natural history of hepatitis C. Semin. Liver Dis. 24 Suppl. 2 (2004) 3-8
2. Bukh J., Miller R.H., and Purcell R.H. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15 (1995) 41-63
3. Chang K.M., Rehermann B., McHutchison J.G., Pasquinelli C., Southwood S., Sette A., and Chisari F.V. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100 (1997) 2376-2385
4. Chen S., and Wang Y.M. Evolutionary study of hepatitis C virus envelope genes during primary infection. Chin. Med. J. (Engl.) 120 (2007) 2174-2180
5. Cuevas J.M., Torres-Puente M., Jiménez-Hernández N., Bracho M.A., García-Robles I., Carnicer F., del Olmo J., Ortega E., González-Candelas F., and Moya A. Combined therapy of interferon plus ribavirin promotes multiple adaptive solutions in hepatitis C virus. J. Med. Virol. 81 (2009) 650-656
6. Cuevas J.M., Torres-Puente M., Jiménez-Hernández N., Bracho M.A., García-Robles I., Carnicer F., del Olmo J., Ortega E., Moya A., and González-Candelas F. Refined analysis of genetic variability parameters in hepatitis C virus and the ability to predict antiviral treatment response. J. Viral Hepat. 15 (2008) 578-590
7. Cuevas J.M., Torres-Puente M., Jiménez-Hernández N., Bracho M.A., García-Robles I., Wrobel B., Carnicer F., del Olmo J., Ortega E., Moya A., and González-Candelas F. Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin. Plos One 3 (2008) e3058
8. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130 (2006) 231-264
9. Durante M.E., Forton D.M., Ruggiero G., and Karayiannis P. Hepatitis C virus E2 and NS5A region variability during sequential treatment with two interferon-alpha preparations. J. Med. Virol. 70 (2003) 62-73
10. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Ogura Y., Izumi N., Marumo F., and Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N. Engl. J. Med. 334 (1996) 77-81
11. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., and Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 (2000) 339-344
12. Fournillier A., Wychowski C., Boucreux D., Baumert T.F., Meunier J.C., Jacobs D., Muguet S., Depla E., and Inchauspe G. Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J. Virol. 75 (2001) 12088-12097
13. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., and Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347 (2002) 975-982
14. Gale Jr. M.J., Korth M.J., and Katze M.G. Repression of the PKR protein kinase by the hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin. Diagn. Virol. 10 (1998) 157-162
15. Gale Jr. M.J., Korth M.J., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., Polyak S.J., Gretch D.R., and Katze M.G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
16. Goyal A., Hofmann W.P., Hermann E., Traver S., Hissar S.S., Arora N., Blum H.E., Zeuzem S., Sarrazin C., and Sarin S.K. The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India. Med. Microbiol. Immunol. 196 (2007) 11-21
17. Hanada K., Tanaka Y., Mizokami M., Gojobori T., and Alter H.J. A reduction in selective immune pressure during the course of chronic hepatitis C correlates with diminished biochemical evidence of hepatic inflammation. Virology 361 (2007) 27-33
18. Heathcote J., and Main J. Treatment of hepatitis C. J. Viral Hepat. 12 (2005) 223-235
19. Hofmann W.P., Zeuzem S., and Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J. Clin. Virol. 32 (2005) 86-91
20. Inchauspe G., Zebedee S., Lee D.H., Sugitani M., Nasoff M., and Prince A.M. Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 10292-10296
21. Jiménez-Hernández N., Torres-Puente M., Bracho M.A., García-Robles I., Ortega E., del Olmo J., Carnicer F., Gonzalez-Candelas F., and Moya A. Epidemic dynamics of two coexisting hepatitis C virus subtypes. J. Gen. Virol. 88 (2007) 123-133
22. Kato N., Ootsuyama Y., Tanaka T., Nakagawa M., Nakazawa T., Muraiso K., Ohkoshi S., Hijikata M., and Shimotohno K. Marked sequence diversity in the putative envelope proteins of hepatitis C viruses. Virus Res. 22 (1992) 107-123
23. Klenerman P., Lechner F., Kantzanou M., Ciurea A., Hengartner H., and Zinkernagel R. Viral escape and the failure of cellular immune responses. Science 289 (2000) 2003
24. Korber B., and Myers G. Signature pattern analysis: a method for assessing viral sequence relatedness. AIDS Res. Hum. Retroviruses 8 (1992) 1549-1560
25. Lindenbach B.D., and Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 436 (2005) 933-938
26. Missale G., Cariani E., and Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?. Dig Liver Dis. 36 (2004) 703-711
27. Nousbaum J., Polyak S.J., Ray S.C., Sullivan D.G., Larson A.M., Carithers Jr. R.L., and Gretch D.R. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J. Virol. 74 (2000) 9028-9038
28. Ohno O., Mizokami M., Wu R.R., Saleh M.G., Ohba K., Orito E., Mukaide M., Williams R., and Lau J.Y. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a 3b 4 5a, and 6a. J. Clin. Microbiol. 35 (1997) 201-207
29. Okamoto H., Kojima M., Okada S., Yoshizawa H., Iizuka H., Tanaka T., Muchmore E.E., Peterson D.A., Ito Y., and Mishiro S. Genetic drift of hepatitis C virus during an 8 2-year infection in a chimpanzee: variability and stability. Virology 190 (1992) 894-899
30. Pascu M., Martus P., Hohne M., Wiedenmann B., Hopf U., Schreier E., and Berg T. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 53 (2004) 1345-1351
31. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5 (2005) 558-567
32. Sheridan I., Pybus O.G., Holmes E.C., and Klenerman P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J. Virol. 78 (2004) 3447-3454
33. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25 (1997) 4876-4882
34. Torres-Puente M., Cuevas J.M., Jiménez-Hernández N., Bracho M.A., García-Robles I., Carnicer F., del Olmo J., Ortega E., Moya A., and González-Candelas F. Contribution of insertions and deletions to the variability of hepatitis C virus populations. J. Gen. Virol. 88 (2007) 2198-2203
35. Torres-Puente M., Cuevas J.M., Jiménez-Hernández N., Bracho M.A., García-Robles I., Carnicer F., del Olmo J., Ortega E., Moya A., and González-Candelas F. Hepatitis C virus and the controversial role of the interferon sensitivity determining region in the response to interferon treatment. J. Med. Virol. 80 (2008) 247-253
36. Torres-Puente M., Cuevas J.M., Jiménez-Hernández N., Bracho M.A., García-Robles I., Wrobel B., Carnicer F., del Olmo J., Ortega E., Moya A., and González-Candelas F. Genetic variability in hepatitis C virus and its role in antiviral treatment response. J. Viral Hepat. 15 (2008) 188-199
37. Torres-Puente M., Cuevas J.M., Jiménez-Hernández N., Bracho M.A., Garcia-Robles I., Wrobel B., Carnicer F., del Olmo J., Ortega E., Moya A., and Gonzalez-Candelas F. Using evolutionary tools to refine the new hypervariable region 3 within the envelope 2 protein of hepatitis C virus. Infect. Genet. Evol. 8 (2008) 74-82
38. Troesch M., Meunier I., Lapierre P., Lapointe N., Alvarez F., Boucher M., and Soudeyns H. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein. Virology 352 (2006) 357-367
39. Tseng C.T., and Klimpel G.R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 195 (2002) 43-49
40. Wack A., Soldaini E., Tseng C., Nuti S., Klimpel G., and Abrignani S. Binding of the hepatitis C virus envelope protein E2 to CD81 provides a co-stimulatory signal for human T cells. Eur. J. Immunol. 31 (2001) 166-175
41. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin. Liver Dis. 20 (2000) 1-16